Baolan Li

Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute

SCHOLARLY PAPERS

3

DOWNLOADS

191

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with EGFR-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study

Number of pages: 38 Posted: 18 Mar 2022
Shanghai Jiao Tong University (SJTU) - Shanghai Lung Cancer Center, Central South University - Thoracic Medicine Department II, Shanghai Jiao Tong University (SJTU) - Department of Medical Oncology, Jilin Cancer Hospital - Department of Oncology, Zhengzhou University - Henan Cancer Hospital, Peking University - Department of Thoracic Medical Oncology, Peking University - Department of Thoracic Medical Oncology, Huazhong University of Science and Technology - Hubei Cancer Hospital, Shandong First Medical University - Department of Oncology, Xuzhou Central Hospital, Nanjing University - Department of Respiratory Medicine, Hebei Medical University, Jilin University (JLU) - Cancer Center, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Zhengzhou University - Department of Oncology, Xiamen University, Nanjing University, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information, Eli Lilly and Company, Ltd - Department of Oncology Medical Strategy, Eli Lilly and Company, Ltd - Clinical Design, Delivery & Analytics, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information and Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology
Downloads 95 (563,994)

Abstract:

Loading...

sintilimab, IBI305, NSCLC, EGFR

2.

Intergration of Clinical and Blood Parameters in Risk Prognostication for Patients Receiving Immunochemotherapy for Extensive Stage Small Cell Lung Cancer: Real-World Data from Two Centers

Number of pages: 29 Posted: 30 Jan 2024
Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Cancer Centre, Shaanxi Hospital of Traditional Chinese Medicine, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Cancer Centre, Capital Medical University - Cancer Centre, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute and Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute
Downloads 51 (781,361)

Abstract:

Loading...

extensive stage small cell lung cancer, immunochemotherapy, real-world studies, predictive models, biomarkers

3.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (824,020)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker